Targeting the immune microenvironment to treat KRAS-mutant adenocarcinoma

Targeting the immune microenvironment to treat KRAS-mutant adenocarcinoma

Project details

Lung cancer is the leading cause of cancer-related death worldwide. Lung adenocarcinoma is the most common subtype of lung cancer with 35 per cent of cancers associated with oncogenic driver mutations in KRAS (TCGA, Nature 2014 511(7511):320). We have recently identified that pro-tumourigenic macrophages infiltrate KRAS-mutant lung adenocarcinoma, and their depletion can restrict tumour development (Best, Nature Communications 2019 10(1):4190).

This project will explore therapeutic modalities that can inhibit macrophage development and infiltration in KRAS-mutant lung adenocarcinoma to further the clinical translation of our findings.

This project will involve the use of a wide variety of experimental techniques, including pre-clinical models of lung cancer, tissue/tumour pathology, microscopy and flow cytometry.

About our research group

The Sutherland laboratory is embedded within the ACRF Cancer Biology and Stem Cells division and has a strong background in in vivo models of lung cancer. We have made seminal contributions into the identification of the cell-of-origin of lung cancer (Sutherland, PNAS 2014 111(13):4952; Sutherland, Cancer Cell 2011 19(6):754; Sutherland, Mol Oncol. 2010 4(5):397) and have a strong interest in identifying novel oncogenes and tumour suppressor genes in lung cancer development (Best, Oncogene 2018 37(46):6096; Best, Cell Metabolism 2018 27(4):935). We use in vivo models to identify and evaluate therapeutic approaches with the overarching goal of translating these findings to improve treatments for lung cancer patients (Best, Cell Metabolism 2018 27(4):935; Best, Nature Communications 2019 10(1):4190; Best, Journal of Thoracic Oncology 2020).


Email supervisors



Dr Sarah Best in the lab
ACRF Cancer Biology & Stem Cells division

Project Type: